Alaunos Therapeutics Inc (TCRT) Stock Price, Quote & News

Company Profile

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression. In addition, the company develops hunTR TCR discovery platform to target driver mutations. Alaunos T...

Industry: Biotechnology

Sector: Healthcare

Phone: 346 355 4099

Website: www.alaunos.com

Address:

2617 Bissonnet Street, Suite 233, Houston, United States

makedatbread88 Nov. 11 at 6:45 PM

$TCRT abnormal volume keep an eye!

1 · Reply

isnarla Nov. 11 at 2:59 PM

$TCRT finally moving

0 · Reply

LesleyMoore494 Oct. 21 at 4:51 PM

$TCRT progressing in cancer therapy; AITX progressing in AI therapy for industries — clear proof of discipline and growth.

0 · Reply

shay7557 Oct. 17 at 2:34 PM

$SGMO Sold the other half. Learned my lesson with $TCRT

1 · Reply

coldfacts Oct. 16 at 8:32 PM

$TCRT 👀

0 · Reply

Eliba Oct. 16 at 3:52 PM

$TCRT Now it's a very cheap price compared to the near future, money on the floor 🔥⬆️

0 · Reply

Viktor1234 Oct. 16 at 10:58 AM

$TCRT Can we expect another pump soon here?

0 · Reply

nerowinger Oct. 14 at 3:19 PM

$TCRT added

0 · Reply

DepressedStonksTrader Oct. 11 at 3:01 PM

$ATCH $BAOS $CDT $TCRT We’re not either!!

0 · Reply

DajTrader Oct. 11 at 11:31 AM

$ATCH $BAOS $CDT $TCRT Struggling to make money? Were not!

0 · Reply

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering

May 14, 2025, 8:00 AM EDT - 6 months ago

PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)

ELAB

Nov 14, 2023, 7:30 AM EST - 2 years ago

Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives

Aug 21, 2023, 7:32 AM EDT - 2 years ago

Top 5 Health Care Stocks That Could Blast Off This Month - Allakos (NASDAQ:ALLK), BioLife Solns (NASDAQ:BLFS)

ALLK BLFS KZR

Aug 14, 2023, 4:05 PM EDT - 2 years ago

Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives

Jun 29, 2023, 7:00 AM EDT - 2 years ago

Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies

May 25, 2023, 5:00 PM EDT - 2 years ago

Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting

May 10, 2023, 3:40 PM EDT - 2 years ago

Alaunos Therapeutics, Inc. (TCRT) Q1 2023 Earnings Call Transcript

May 10, 2023, 7:00 AM EDT - 2 years ago

Alaunos Therapeutics Reports First Quarter 2023 Financial Results

May 3, 2023, 8:30 AM EDT - 2 years ago

Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023

Apr 26, 2023, 12:30 PM EDT - 2 years ago

Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Mar 30, 2023, 7:00 AM EDT - 2 years ago

Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors

Mar 29, 2023, 5:30 PM EDT - 2 years ago

Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April

Mar 7, 2023, 10:35 AM EST - 2 years ago

Alaunos Therapeutics, Inc. (TCRT) Q4 2022 Earnings Call Transcript

Mar 7, 2023, 7:00 AM EST - 2 years ago

Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Feb 28, 2023, 4:01 PM EST - 2 years ago

Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023

Jan 9, 2023, 8:30 AM EST - 3 years ago

Alaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023

Nov 29, 2022, 9:01 AM EST - 3 years ago

Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock

Nov 28, 2022, 4:01 PM EST - 3 years ago

Alaunos Therapeutics Announces Proposed Public Offering of Common Stock

Nov 21, 2022, 2:13 PM EST - 3 years ago

Alaunos Therapeutics Still Waiting For Home Run

Nov 14, 2022, 2:10 PM EST - 3 years ago

Alaunos Therapeutics, Inc. (TCRT) Q3 2022 Earnings Call Transcript

Nov 14, 2022, 7:00 AM EST - 3 years ago

Alaunos Therapeutics Reports Third Quarter 2022 Financial Results

Nov 8, 2022, 8:30 AM EST - 3 years ago

Alaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022

Nov 7, 2022, 8:00 AM EST - 3 years ago

Alaunos Therapeutics to Present Data Highlighting its hunTR™ TCR Discovery Platform at the Society for Immunotherapy of Cancer 2022 Annual Meeting

Sep 21, 2022, 8:30 AM EDT - 3 years ago

Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference

Sep 14, 2022, 9:28 PM EDT - 3 years ago

Alaunos Therapeutics - T-Cell Therapies

Sep 7, 2022, 8:30 AM EDT - 3 years ago

Alaunos Therapeutics to Participate in Upcoming Investor Conferences in September

Aug 31, 2022, 4:00 PM EDT - 3 years ago

Alaunos: Taking Autologous T-Cell Receptor Therapies To The Next Step

Aug 24, 2022, 3:00 PM EDT - 3 years ago

Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference

Aug 15, 2022, 12:01 PM EDT - 3 years ago

Alaunos Therapeutics, Inc. (TCRT) CEO Kevin Boyle on Q2 2022 Results - Earnings Call Transcript

Aug 15, 2022, 7:00 AM EDT - 3 years ago

Alaunos Therapeutics Reports Second Quarter 2022 Financial Results

Aug 8, 2022, 8:50 AM EDT - 3 years ago

Alaunos Therapeutics to Report Second Quarter 2022 Financial Results on August 15, 2022

Aug 4, 2022, 5:00 PM EDT - 3 years ago

Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations

Jun 1, 2022, 11:39 AM EDT - 3 years ago

CellChorus Announces Scientific Advisory Board

Jun 1, 2022, 8:30 AM EDT - 3 years ago

Alaunos Therapeutics to Present at the Jefferies Healthcare Conference

May 26, 2022, 5:01 PM EDT - 3 years ago

Alaunos Therapeutics to Present Trials in Progress Poster for its TCR-T Library Phase 1/2 trial at the 2022 American Society of Clinical Oncology Annual Meeting

May 16, 2022, 12:31 PM EDT - 3 years ago

Alaunos Therapeutics, Inc. (TCRT) CEO Kevin Boyle on Q1 2022 Results - Earnings Call Transcript

May 16, 2022, 7:30 AM EDT - 3 years ago

Alaunos Therapeutics Reports First Quarter 2022 Financial Results

May 10, 2022, 8:30 AM EDT - 3 years ago

Alaunos Therapeutics to Present at the H.C. Wainwright Global Investment Conference

May 9, 2022, 8:30 AM EDT - 3 years ago

Alaunos Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022

May 2, 2022, 4:31 PM EDT - 3 years ago

Alaunos Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting

May 2, 2022, 8:30 AM EDT - 3 years ago

Alaunos Therapeutics Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid Tumors

Mar 30, 2022, 11:38 AM EDT - 3 years ago

Alaunos Therapeutics, Inc. (TCRT) Kevin Boyle on Q4 2021 Results - Earnings Call Transcript

Mar 30, 2022, 7:30 AM EDT - 3 years ago

Alaunos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Mar 16, 2022, 8:30 AM EDT - 3 years ago

Alaunos Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 30, 2022

Mar 8, 2022, 4:05 PM EST - 4 years ago

Alaunos Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference

Jan 26, 2022, 11:19 AM EST - 4 years ago

Ziopharm Rebrands As Alaunos Therapeutics

Jan 26, 2022, 7:00 AM EST - 4 years ago

Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos Therapeutics

Nov 9, 2021, 8:05 AM EST - 4 years ago

Ziopharm Oncology Presents Preclinical Data Supporting TCR-T Library Approach at the Society for Immunotherapy of Cancer 2021 Annual Meeting

Nov 8, 2021, 7:45 PM EST - 4 years ago

ZIOPHARM Oncology, Inc. (ZIOP) CEO Kevin Boyle on Q3 2021 Results - Earnings Call Transcript

makedatbread88 Nov. 11 at 6:45 PM

$TCRT abnormal volume keep an eye!

1 · Reply

isnarla Nov. 11 at 2:59 PM

$TCRT finally moving

0 · Reply

LesleyMoore494 Oct. 21 at 4:51 PM

$TCRT progressing in cancer therapy; AITX progressing in AI therapy for industries — clear proof of discipline and growth.

0 · Reply

shay7557 Oct. 17 at 2:34 PM

$SGMO Sold the other half. Learned my lesson with $TCRT

1 · Reply

coldfacts Oct. 16 at 8:32 PM

$TCRT 👀

0 · Reply

Eliba Oct. 16 at 3:52 PM

$TCRT Now it's a very cheap price compared to the near future, money on the floor 🔥⬆️

0 · Reply

Viktor1234 Oct. 16 at 10:58 AM

$TCRT Can we expect another pump soon here?

0 · Reply

nerowinger Oct. 14 at 3:19 PM

$TCRT added

0 · Reply

DepressedStonksTrader Oct. 11 at 3:01 PM

$ATCH $BAOS $CDT $TCRT We’re not either!!

0 · Reply

DajTrader Oct. 11 at 11:31 AM

$ATCH $BAOS $CDT $TCRT Struggling to make money? Were not!

0 · Reply

SqueezeRib Oct. 10 at 12:36 PM

$TCRT damn

0 · Reply

Ron_Burn Oct. 10 at 3:18 AM

$TCRT might buy if she hit $2 today

0 · Reply

StockScanners Oct. 10 at 2:30 AM

$TCRT reached 8.11, dam son lets go team, be ready for next idea

0 · Reply

Viktor1234 Oct. 9 at 10:23 PM

$TCRT What happened to this? Should have been careful.

0 · Reply

waitfordump Oct. 9 at 9:04 PM

$TCRT what a garbage stock from 8 to 3.70

0 · Reply

DreamCreator Oct. 9 at 8:09 PM

Keep a close watch on CMCT! $SIDU $UBER $TCRT $ALAB ll

0 · Reply

DreamCreator Oct. 9 at 7:30 PM

Keep a close watch on CMCT! $VZ $TCRT $UBER $SNDK k

0 · Reply

Tazdoc88 Oct. 9 at 6:50 PM

$TCRT

0 · Reply

SqueezeRib Oct. 9 at 6:48 PM

$TCRT Again!

0 · Reply

PaulLaurent Oct. 9 at 6:45 PM

📢📊 Unusual Volume Stocks 📊📢 $JFU $AMBO $TCRT $BDRX $ATHE

0 · Reply

chinchinbull Oct. 9 at 5:16 PM

Afternoon movers $CETY VS $NUAI VS $BAOS vs $TCRT

0 · Reply

KiaShipman1066 Oct. 9 at 5:05 PM

$TCRT may be innovative in biotech, but AITX is innovating across entire industries — construction, banking, logistics, healthcare — real enterprise contracts, not concepts.

0 · Reply

Market Cap	6.94M
Revenue (ttm)	10,000.00
Net Income (ttm)	-4.68M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-46,800.00%
Debt to Equity Ratio	0.00

Volume	34,500
Avg Vol	532,608
Day's Range	N/A - N/A
Shares Out	2.32M
Stochastic %K	64%
Beta	-0.90
Analysts	Strong Buy
Price Target	$3.00